1Kingma PS, Whitsett JA. Indefense of the lung: surfactant protein A and surfactant protein D. Curr Opin Pharmacol, 2006,6 : 277-283.
2Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol,2005,5:58-68.
3Halliday HL. History of surfactant from 1980. Biol Neonate, 2005,87 : 317-322.
4Mailoy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr, 2005, 94:779- 784.
5Baroutis G, Kaleyias J, Liarou T, et al. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr, 2003,162 : 476-480.
6Stevens TP, Harrington EW, Blennow M, et al. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev, 2007, (4):CD003063.
7Verder H. Nasal CPAP has become an indispensable part of the primary treatment of newborns with respiratory distress syndrome. Acta Paediatr, 2007,96:482-484.
8Curstedt T, Johansson J. New synthetic surfactant how and when? Biol Neonate,2006,89:336 -339.
9Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics, 2005,115:1018-1029.
10Sinha SK, Lacaze-Masmonteil T, Valli S Soler AV, et al. A multicenter randomized, controlled trial of lucinactant versus poraetant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics, 2005, 115: 1030- 1038.
